These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9559820)

  • 1. Killing of Staphylococcus aureus by C-8-methoxy fluoroquinolones.
    Zhao X; Wang JY; Xu C; Dong Y; Zhou J; Domagala J; Drlica K
    Antimicrob Agents Chemother; 1998 Apr; 42(4):956-8. PubMed ID: 9559820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
    Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of the C-8-methoxy group of gatifloxacin to inhibition of type II topoisomerases of Staphylococcus aureus.
    Takei M; Fukuda H; Kishii R; Kadowaki Y; Atobe Y; Hosaka M
    Antimicrob Agents Chemother; 2002 Oct; 46(10):3337-8. PubMed ID: 12234876
    [No Abstract]   [Full Text] [Related]  

  • 4. Topoisomerase mutations in trovafloxacin-resistant Staphylococcus aureus.
    Fitzgibbon JE; John JF; Delucia JL; Dubin DT
    Antimicrob Agents Chemother; 1998 Aug; 42(8):2122-4. PubMed ID: 9687420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quinolone resistance mutations in the GrlB protein of Staphylococcus aureus.
    Tanaka M; Onodera Y; Uchida Y; Sato K
    Antimicrob Agents Chemother; 1998 Nov; 42(11):3044-6. PubMed ID: 9797253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus.
    Lu T; Zhao X; Li X; Drlica-Wagner A; Wang JY; Domagala J; Drlica K
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2703-9. PubMed ID: 11557458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus.
    Schedletzky H; Wiedemann B; Heisig P
    J Antimicrob Chemother; 1999 May; 43 Suppl B():31-7. PubMed ID: 10382873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.
    Ng EY; Trucksis M; Hooper DC
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1881-8. PubMed ID: 8843298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases.
    Blanche F; Cameron B; Bernard FX; Maton L; Manse B; Ferrero L; Ratet N; Lecoq C; Goniot A; Bisch D; Crouzet J
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2714-20. PubMed ID: 9124828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topoisomerase mutations in fluoroquinolone-resistant and methicillin-susceptible and -resistant clinical isolates of Staphylococcus aureus.
    Kaatz GW; Seo SM
    Antimicrob Agents Chemother; 1998 Jan; 42(1):197-8. PubMed ID: 9449288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibacterial activities and inhibitory effects of sitafloxacin (DU-6859a) and its optical isomers against type II topoisomerases.
    Akasaka T; Kurosaka S; Uchida Y; Tanaka M; Sato K; Hayakawa I
    Antimicrob Agents Chemother; 1998 May; 42(5):1284-7. PubMed ID: 9593169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activities of 13 fluoroquinolones against Staphylococcus aureus isolates with characterized mutations in gyrA, gyrB, grlA, and norA and against wild-type isolates.
    Muñoz Bellido JL; Alonso Manzanares MA; Yagüe Guirao G; Gutiérrez Zufiaurre MN; Toldos MC; Segovia Hernández M; Garcia-Rodríguez JA
    Antimicrob Agents Chemother; 1999 Apr; 43(4):966-8. PubMed ID: 10103212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.
    Ferrero L; Cameron B; Manse B; Lagneaux D; Crouzet J; Famechon A; Blanche F
    Mol Microbiol; 1994 Aug; 13(4):641-53. PubMed ID: 7997176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group.
    Lu T; Zhao X; Drlica K
    Antimicrob Agents Chemother; 1999 Dec; 43(12):2969-74. PubMed ID: 10582891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Action of quinolones against Staphylococcus aureus topoisomerase IV: basis for DNA cleavage enhancement.
    Anderson VE; Zaniewski RP; Kaczmarek FS; Gootz TD; Osheroff N
    Biochemistry; 2000 Mar; 39(10):2726-32. PubMed ID: 10704224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of mutations in grlA and gyrA topoisomerase genes with resistance to ciprofloxacin in epidemic and sporadic isolates of methicillin-resistant Staphylococcus aureus.
    Deplano A; Zekhnini A; Allali N; Couturier M; Struelens MJ
    Antimicrob Agents Chemother; 1997 Sep; 41(9):2023-5. PubMed ID: 9303407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel quinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.
    Mitton-Fry MJ; Brickner SJ; Hamel JC; Brennan L; Casavant JM; Chen M; Chen T; Ding X; Driscoll J; Hardink J; Hoang T; Hua E; Huband MD; Maloney M; Marfat A; McCurdy SP; McLeod D; Plotkin M; Reilly U; Robinson S; Schafer J; Shepard RM; Smith JF; Stone GG; Subramanyam C; Yoon K; Yuan W; Zaniewski RP; Zook C
    Bioorg Med Chem Lett; 2013 May; 23(10):2955-61. PubMed ID: 23566517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of action and resistance of older and newer fluoroquinolones.
    Hooper DC
    Clin Infect Dis; 2000 Aug; 31 Suppl 2():S24-8. PubMed ID: 10984324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux-mediated resistant mutants of Staphylococcus aureus.
    Takenouchi T; Tabata F; Iwata Y; Hanzawa H; Sugawara M; Ohya S
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1835-42. PubMed ID: 8843290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity.
    Fournier B; Hooper DC
    Antimicrob Agents Chemother; 1998 Jan; 42(1):121-8. PubMed ID: 9449271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.